GlassScriptPhysician profile
Brent A Barnes
NPI 1114170248
$4,676.74
in general payments reported to CMS, 2019-2025
32 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $425 · 2021: $648 · 2022: $985 · 2023: $629 · 2024: $512 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $783.12 | 2019-2025 | Lifevest |
| Abbott Laboratories | $547.88 | 2020-2025 | Navitor, Diamondback Coronary, Jot Dx |
| Janssen Pharmaceuticals, INC | $459.08 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $347.66 | 2019-2024 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $277.92 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $263.35 | 2019-2024 | |
| Abiomed | $263.06 | 2021-2025 | Impella |
| Amgen INC. | $226.74 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $201.78 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $171.13 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $169.58 | 2019-2025 | Farxiga, Lokelma |
| Medtronic, INC. | $121.95 | 2021-2025 | Corevalve Evolut R |
| Cardiovascular Systems INC. | $121.69 | 2019-2021 | |
| Amarin Pharma, INC. | $98.22 | 2020-2022 | |
| Cardinal Health 200 LLC | $91.80 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $89.79 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $63.66 | 2022-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.64 | 2020-2022 | |
| Smith+Nephew, INC. | $52.41 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $45.38 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $41.11 | 2019-2020 | |
| Chiesi USA, INC. | $27.67 | 2022 | |
| Daiichi Sankyo INC. | $19.63 | 2022 | |
| Acist Medical Systems, INC. | $18.05 | 2023 | |
| Esperion Therapeutics, INC. | $17.93 | 2021 | |
| Ge Healthcare | $16.04 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.00 | 2023 | Inpefa |
| Haemonetics Corporation | $15.02 | 2020 | |
| Tactile Systems Technology INC | $14.85 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $14.40 | 2023 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $14.04 | 2019 | |
| Impulse Dynamics (USA) INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.